KDM6B and head and neck squamous cell carcinoma: To conclude, we validated the putative therapeutic potential of GSK-J1 for radiosensitization of HNSCC cells and identified its targets UTX (KDM6A) and JMJD3 (KDM6B) as potential prognostic biomarkers in HNSCC patients undergoing radiotherapy.